// App-Quantinova.ai

Abstract P682 : Risk of All Cause Stroke and Major Bleeding Events When Switching From Warfarin to Apixaban in Patients With Advanced Chronic Kidney Disease and Prevalent Atrial Fibrillation

Researchers

Presenter

  • Katherine Garlo

Principal Investigators

  • Thomas Mavrakanas

  • Elisabeth Burdick

  • Wei Wang

  • David Charytan

Medical Centers

  • Alexion, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Transient Ischemic Attack

  • Chronic kidney disease

  • Arrhythmia

  • Venous thrombosis

  • Renal disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • apixaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved